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Abstract The multifaceted nature of the pathology of demen-
tia spectrum disorders has complicated their management and
the development of effective treatments. This is despite the
fact that they are far from uncommon, with Alzheimer’s dis-
ease (AD) alone affecting 35 million people worldwide. The
cholinergic system has been found to be crucially involved in
cognitive function, with cholinergic dysfunction playing a
pivotal role in the pathophysiology of dementia. The use of
molecular imaging such as SPECT and PET for tagging tar-
gets within the cholinergic system has shown promise for
elucidating key aspects of underlying pathology in dementia
spectrum disorders, including AD or parkinsonian dementias.
SPECT and PET studies using selective radioligands for cho-
linergic markers, such as [11C]MP4A and [11C]PMP PET for
acetylcholinesterase (AChE), [123I]5IA SPECT for the α4β2
nicotinic acetylcholine receptor and [123I]IBVM SPECT for
the vesicular acetylcholine transporter, have been developed
in an attempt to clarify those aspects of the diseases that re-
main unclear. This has led to a variety of findings, such as
cortical AChE being significantly reduced in Parkinson’s dis-
ease (PD), PD with dementia (PDD) and AD, as well as cor-
relating with certain aspects of cognitive function such as
attention and working memory. Thalamic AChE is signifi-
cantly reduced in progressive supranuclear palsy (PSP) and
multiple system atrophy, whilst it is not affected in PD. Some
of these findings have brought about suggestions for the im-
provement of clinical practice, such as the use of a thalamic/
cortical AChE ratio to differentiate between PD and PSP, two
diseases that could overlap in terms of initial clinical presen-
tation. Here, we review the findings from molecular imaging
studies that have investigated the role of the cholinergic sys-
tem in dementia spectrum disorders.
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Introduction
The population of the developed world is ageing and this has
led to an increasing prevalence of dementia. It has recently
been estimated that 47.5million people worldwide suffer from
dementia [1]. Dementia is a challenge to society, both in terms
of economic cost and social burden, as most patients require
long-term care in their home or nursing home [2]. There is
clearly a real incentive to find more effective methods of di-
agnosing and treating this set of diseases, which are not yet as
fully understood as many of their other neurodegenerative
diseases.
The cholinergic system plays a key role in functional and
structural remodelling of cortical circuits underlying cognitive
processing [3]. The three major cholinergic projection systems
of the central nervous system include (1) the nucleus basalis of
Meynert, which supplies cholinergic projections throughout
the cerebral cortex and hippocampus [4], (2) the
pedunculopontine nucleus pars compacta, which projects to
the forebrain as well as various subcortical structures such as
the thalamus [5], and (3) cholinergic neurons intrinsic to the
striatum [6]. Post-mortem studies have found that muscarinic
acetylcholine receptors (mAChR) are highly expressed in the
caudate nucleus and nucleus accumbens in normal monkey
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and human brain [7–9]. In the somatosensory, primary motor
and temporal cortices, mAChR concentrations are about 60 %
of the levels in the caudate whilst the cerebellar cortex ex-
presses the lowest levels [8]. Nicotinic acetylcholine receptors
(nAChR) are abundantly expressed in the entorhinal, temporal
and primary motor cortices, and the hippocampus and thala-
mus of post-mortem normal human brain tissue [10–12].
Dysfunction of the ascending cholinergic systems from the
basal forebrain and brainstem and the associated loss of cho-
linergic neurotransmission in the cerebral cortex has been sug-
gested as an underlying substrate of cognitive decline (cholin-
ergic hypothesis of dementia), supporting the use of acetyl-
cholinesterase (AChE) inhibitors in dementia [13]. Many
post-mortem studies investigating pathophysiological mecha-
nisms of dementia have focused on alterations in functional
components of the cholinergic system, such as AChE, the
vesicular acetylcholine transporter (VAChT), nAChR, and
mAChR [14, 15]. Molecular imaging techniques such as
SPECT and PETwith selective radioligands for targets within
the cholinergic system have led to significant advances in the
understanding of the neurobiology and pathophysiology of
dementia (Fig. 1).
This review discusses the use of cholinergic radioligands in
molecular imaging (Tables 1 and 2), with the aim of improv-
ing the understanding, and thereby the diagnosis, monitoring
and treatment, of dementia spectrum disorders.
Cholinergic system in Alzheimer’s disease
AD is the leading cause of dementia in the western world,
accounting for more than 60 % of cases [44, 45]. AD is char-
acterized pathologically by accumulation of amyloid β pep-
tide (Aβ) in extracellular plaques, intracellular deposits of tau
protein, and neuronal loss [46–48]. Evidence for the involve-
ment of the cholinergic system in the pathogenesis of AD was
provided as early as the mid-1970s in post-mortem studies
showing loss of choline acetyltransferase (ChAT) and AChE
in the cortex, hippocampus and amygdala of AD brain sam-
ples [14, 49–50]. Moreover, reduced ChAT activity has been
found to be correlated with increased Aβ plaque load and with
cognitive decline [50, 52]. Degeneration of the cholinergic
system affects not only cortical regions but also the nucleus
basalis of Meynert, where cholinergic neurons are severely
decreased in post-mortem brain tissue of AD patients,
highlighting the role of subcortical cholinergic dysfunction
in the pathogenesis of AD [53].
Presynaptic cholinergic dysfunction in Alzheimer’s
disease
PET with N-[11C]methyl-piperidin-4-yl propionate
([11C]PMP), a selective substrate for AChE [54], has shown
a reduction in AChE activity in AD patients [17, 19, 20]. The
degree of AChE activity reduction ranged between 9 % and
33 %, depending on the severity of cognitive impairment in
the cohort of AD patients examined. Kuhl et al. [17] found
decreases in neocortical and hippocampal AChE activity of
25 – 33 % in patients with moderate–severe AD and a mean
Mini Mental State Examination (MMSE) score of 14. Loss of
cortical [11C]PMP uptake is associated with reductions in
VAChT, as measured by 5-[123I]iodo-benzovesamicol
([123I]IBVM) SPECT, but does not correlate with decreases
in 2-[18F]-fluoro-2-deoxy-D-glucose ([18F]FDG) PET, which
is focally reduced in the posterior cingulate gyrus and parietal
cortex [17]. The disagreement in cholinergic and metabolic
imaging patterns of degeneration suggests a different mecha-
nism underlying cholinergic and metabolic decline in AD
pathophysiology. Patients with early AD (mean MMSE score
22) showed more modest reductions in cortical AChE activity
(9 – 11%) with greater decreases in the lateral temporal cortex
(15 %) [19, 20]. Overall, in vivo AChE losses tend to be less
pronounced than those seen in post-mortem studies, in which
55 % reductions in cholinergic markers have been observed
[55].
The modest degree of cholinergic denervation despite the
severity of cognitive decline raises questions about the specif-
ic role of the cholinergic system in episodic memory process-
es. In this regard, Bohnen et al. [20] found that decreases in
cortical AChE activity were negatively correlated with perfor-
mance in the WAIS-III digit span test, whereas they were not
Fig. 1 Schematic illustration of PET and SPECT techniques assessing
presynaptic and postsynaptic cholinergic molecular targets with direct
relevance to dementia. Acetylcholine (ACh) is degraded to choline and
acetate by acetylcholinesterase (AChE), thereby terminating
neurotransmission. The reuptake of choline into the presynaptic neuron
occurs via a choline transporter. Choline is recycled within the
presynaptic neuron to form ACh and stored in vesicles through a
presynaptic vesicular ACh transporter (VAChT). Two different types of
ACh receptors (AChR) are expressed on the postsynaptic neurons:
nicotinic receptors (nAChR) and muscarinic receptors (mAChR)
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Table 1 Cholinergic PET and SPECT studies using presynaptic cholinergic markers in dementia spectrum disorders
Radiotracer Target Reference Imaging
technique
Subjects Main findings
[123I]IBVM VAChT [16] SPECT 22 AD, 9 PD, 6 PDD, 36 HC Significant reduction in VAChT levels in entire cortex in
PDD; only reduced in parietal and occipital cortex in PD.
In mildly demented AD patients with age of onset <65
years, severe reduction in cortical and hippocampal binding.
In AD patients with age of onset >65 years, VAChT
reductions only in temporal cortex and hippocampus.
[11C]PMP AChE [17] PET 14 AD, 26 HC Significant reduction in cortical AChE activity in AD patients.
No significant changes in AChE activity in caudate, putamen,
thalamus, pons or cerebellum.
[11C]MP4A AChE [18] PET 16 PD, 12 PSP, 13 HC Significant reduction in cortical AChE activity in PD (−17 %);
no significant changes in thalamic [11C]MP4A uptake in PD.
Significant reduction in thalamic AChE activity in PSP
(−38 %) but no significant change in cortical binding.
Possible use of thalamic to cortical [11C]MP4A binding
ratio for the differential diagnosis of PD and PSP.
[11C]PMP AChE [19] PET 12 AD, 11 PD, 14 PDD, 10 HC Highest reduction in cortical AChE activity in PDD (−20 %),
then PD (−12.9 %), and least in AD (−9.1 %). Selective
involvement of lateral temporal cortex in AD (−15 %).
[11C]PMP AChE [20] PET 15 AD, 12 HC Significant reduction in cortical AChE activity in AD patients.
Positive correlation between cortical AChE activity and
attention and working memory; no correlation with short-term
or long-term memory.
[11C]MP4A AChE [21] PET 17 PD, 10 PDD, 31 HC Larger reduction in cortical AChE in PDD (−29.7 %) than in
PD (−10.7 %). Close relationship between striatal
[18F]FDOPA binding and [11C]MP4A binding in frontal and
temporoparietal cortex in PDD.
[11C]MP4A AChE [22] PET 11 AD ApoE4+, 8 AD ApoE4− Larger reduction in AChE activity in ApoE4− than ApoE4+
patients.
[11C]PMP AChE [23] PET 13 PD, 11 PDD, 14 HC Significant reduction in cortical AChE activity in PDD (−20.9 %)
and PD (−12.7 %). Significant correlation between cortical
AChE and WAIS-III Digit Span test, Trail Making test and
Stroop Color Word test scores in PDD. No significant
correlation between motor symptom severity and cortical
binding.
[11C]MP4A AChE [24] PET 18 PD, 10 PDD, 11 DLB, 26 HC Significant reduction in cortical AChE activity in PDD and
DLB (−27 %); no significant difference between PDD and
DLB groups. Significant reduction in cortical binding in PD,
especially in medial occipital cortex (−12 %); significant
difference between PDD and DLB, and PD groups.
[11C]PMP AChE [25] PET 12 PD, 13 MSA, 4 PSP, 22 HC Significant reduction in AChE activity in most cortical regions
in PD (−15.3 %) and MSA (−14.6 %); no significant
differences between PD and MSA groups. No significant
changes in cortical binding in PSP. Preferential denervation of
subcortical structures (striatum, cerebellum, thalamus,
midbrain and pons) in MSA and PSP. Significant reduction in
striatal, cerebellar, thalamic binding in PD, but significantly
smaller reduction than in MSA and PSP.
[11C]MP4A AChE [26] PET 9 PD, 8 PDD, 6 DLB, 3 HC Severe reduction in neocortical AChE activity in PDD and
DLB, with the reduction increasing from frontal (least) to
occipital cortex (most) in both groups. No significant
difference between PDD and DLB groups. Mild cortical
AChE deficit in PD.
[11C]MP4A AChE [27] PET 7 CBD, 12 PSP, 8 FTD, 16 HC Voxel-based analysis showed significant decreases in AChE
activity in CBD (paracentral region, frontal, parietal and
occipital cortices) and PSP (paracentral region and thalamus).
No significant differences in [11C]MP4A binding in FTD.
Volume of interest analysis showed mean cortical AChE
activity reduced by 17.5 % in CBD, 9.4 % in PSP and 4.4 %
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associated with California Verbal Learning Test (CVLT)
scores. These results suggest that cholinergic dysfunction is
linked to attention and working memory rather than episodic
memory. Although cortical cholinergic denervation from the
nucleus basalis of Meynert is a feature of AD, the pontine
cholinergic projection system to the thalamus has been found
to be spared in the disease [28].
PETwith N-[11C]methyl-4-piperidyl acetate ([11C]MP4A),
another selective AChE radioligand, has shown that AD pa-
tients with apolipoprotein E allele ɛ4 (ApoE4) have signifi-
cantly less pronounced reductions in cortical AChE activity
than those negative for the ApoE4 allele [22]. This suggests
that the ApoE4 allele has a protective role against the wide-
spread loss of AChE activity in AD, although the underlying
mechanism remains unknown. [11C]MP4A has shown higher
specificity for AChE relative to butyryl cholinesterase [56,
57], but it has a higher hydrolysis rate and thus radioligand
uptake in regions of high AChE activity such as basal ganglia
is strongly dependent on the rate of transport into the brain
[54]. In contrast, [11C]PMP exhibits a rate of hydrolysis three
to four times slower than that of [11C]MP4A, allowing more
precise estimates of the AChE activity in regions of moderate
to high AChE concentration [58].
SPECTwith [123I]IBVM, a selective ligand for presynaptic
VAChT, has been used to assess presynaptic cholinergic ter-
minal density [59]. Interestingly, in mildly demented AD pa-
tients, the [123I]IBVM binding pattern differs according to age
at onset [16]. In patients with early-onset AD (age at onset
<65 years) loss of cholinergic terminals were observed in the
neocortex and hippocampus, whereas in patients with late-
onset AD significant VAChT reductions were limited to the
temporal cortex and hippocampus. These findings are consis-
tent with those of post-mortem studies, which have demon-
strated more widespread cholinergic degeneration in early-
onset AD [60]. A new PET radioligand with good sensitivity
a n d s p e c i f i c i t y f o r VA C h T , ( − ) 5 - 1 8 F -
fluoroethoxybenzovesamicol ([18F]FEOBV), has recently
been developed and tested in humans [61]. Both reference
tissue modelling and late static scanning approaches correlat-
ed well with the full kinetic modelling with arterial sampling
and plasma metabolite analysis [61]. In comparison with
[123I]IBVM SPECT, [18F]FEOBV PET showed low binding
in the lateral cerebellar cortex and high binding in the
mesopontine junction and medulla, providing a robust index
of VAChT binding [61]. [18F]FEOBV PET is a significant
advance over currently available presynaptic cholinergic im-
aging agents and may be a valuable tool to assess dysregula-
tion of the cholinergic system in AD and parkinsonian
patients.
Postsynaptic cholinergic dysfunction in Alzheimer’s
disease
Previous PET studies using [11C]nicotine have shown signif-
icant reductions in nAChR binding in the frontal cortex, tem-
poral cortex and hippocampus of patients with moderate AD
[62, 63]. Similar to AChE activity, decreases in cortical
nAChR expression as measured by [11C]nicotine are associ-
ated with attention deficit but not episodic memory impair-
ment [32]. These [11C]nicotine studies, however, were hin-
dered by high levels of nonspecific binding, rapid metabolism,
and washout from the brain, as well as a strong dependence on
cerebral blood flow [64, 65]. More recently, new PET and
SPECT radioligands have been developed to target α4β2
nAChR. Post-mortem autoradiography studies have shown
that α4β2 nAChR is the most affected receptor subtype in
AD, with reductions of up to 50% in the neocortex, entorhinal
cortex and hippocampus [12, 66, 67]. [123I]5-iodo-3-[2(S)-2-
azetidinylmethoxy] pyridine ([123I]5IA) SPECT has shown
significant reductions in α4β2 nAChR in the frontal cortex,
striatum, right medial temporal lobe and pons of AD patients
[34]. [123I]5IA binding is also significantly reduced in the
medial temporal cortex of patients with amnestic mild cogni-
tive impairment (MCI) and α4β2 nAChR decreases correlated
Table 1 (continued)
Radiotracer Target Reference Imaging
technique
Subjects Main findings
in FTD; thalamic AChE activity reduced by 24.0 % in PSP but
not in CBD and FTD.
[11C]PMP AChE [28] PET 13 AD, 11 PD, 6 PDD, 6 DLB,
14 HC
Largest reduction in thalamic AChE activity in PDD (−19.8 %),
then in DLB (−17.4 %), least in PD (−12.8 %). Spared
thalamic AChE activity in AD.
[123I]IBVM VAChT [29] SPECT 10 PSP, 12 HC Significant reduction in anterior cingulate cortical,
innominatocortical, thalamic and pontothalamic VAChT
levels Thalamic and pedunculopontine binding inversely
correlated with disease duration.
AChE acetylcholinesterase, AD Alzheimer’s disease, CBD corticobasal degeneration, DLB dementia with Lewy bodies, FTD frontotemporal dementia,
HC healthy control, MSA multiple system atrophy, PD Parkinson’s disease, PDD Parkinson’s disease dementia, PSP progressive supranuclear palsy,
VAChT vesicular acetylcholine transporter
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Table 2 Cholinergic PET and SPECT studies using postsynaptic cholinergic markers in dementia spectrum disorders
Radiotracer Target Reference Imaging
technique
Subjects Main findings
[11C]NMPB mAChR [30] PET 7 PSP, 12 PD, 8 HC Significant increase in mAChR in frontal cortex in PD (22 %).
No significant change in any cortical region in PSP.
[123I]QNB mAChR [31] SPECT 25 PDD, 14 DLB, 24 HC Significant increase in mAChR in right occipital lobe in DLB,
occipital lobes bilaterally in PDD; no significant difference
between DLB and PDD. Significant reduction in mAChR
expression in frontal and temporal lobes in PDD, nonsignificant
in DLB.
[11C]Nicotine nAChR [32] PET 27 AD, 36 HC Significant correlation between cortical nAChR expression and
Digit Symbol test score, as well as Trail Making Test A score.
[123I]5IA α4β2 nAChR [33] SPECT 10 PD, 15 HC Significant widespread reduction in cortical and subcortical
α2β4 nAChR levels in PD (−10 %); highest in thalamus
(−15 %), parietal cortex (−9 %) and temporal cortex
(−8 %); lowest in frontal cortex (−5 %) and occipital
cortex (−3 %). No significant change in K1 (index of
radiotracer delivery).
[123I]5IA α4β2 nAChR [34] SPECT 16 AD, 16 HC Significant reductions in α2β4 nAChR expression in frontal,
striatal, right medial temporal and pontine regions in AD.
[123I]5IA α4β2 nAChR [35] SPECT 10 PD, 10 HC Significant reductions in brainstem and frontal cortex α2β4
nAChR levels in PD (−20 – 25 %). Significant negative
correlation between high daily dose of dopamine agonist
and tracer binding in cerebellum and temporal, parietal
and occipital cortices.
[18F]2FA α4β2 nAChR [36] PET 15 AD, 14 HC No significant change in α2β4 nAChR in early AD compared
to HC; suggestive of nAChR preservation in early stages
of AD.
[123I]5IA α4β2 nAChR [37] SPECT 15 DLB, 16 HC Significant reduction in α2β4 nAChR levels in frontal, temporal,
cingulate cortices and striatum. Significant increase in occipital
cortex expression, correlated with visual hallucinations.
[18F]2FA α4β2 nAChR [38] PET 17 AD, 6 MCI, 10 HC Significant reduction in α2β4 nAChR expression in thalamus,
striatum, cerebellum and cortex of both AD and MCI patients.
Significant negative correlation between [18F]2FA binding
and level of cognitive impairment.
[18F]2FA α4β2 nAChR [39] PET 13 PD, 6 HC Significant reduction in α2β4 nAChR in striatum (−10 %)
and substantia nigra (−14.9 %) in PD.
[18F]2FA α4β2 nAChR [40] PET 22 PD, 9 HC Significant reduction in α2β4 nAChR levels, most pronounced
in the midbrain, pons, anterior cingulate and frontoparietal
cortices, and cerebellum. Significant correlation between
[18F]2FA binding in the anterior cingulate and occipital cortices
and depression. Significant correlation between [18F]2FA
binding in the midbrain, pons and cerebellum and cognitive
impairment.
[123I]5IA α4β2 nAChR [41] SPECT 12 AD, 10 MCI, 10 HC No significant difference in α2β4 nAChR levels in any brain
region investigated (frontal, parietal, anterior cingulate,
temporal and occipital cortices, thalamus, striatum, cerebellum).
[123I]5IA α4β2 nAChR [42] SPECT 10 MCI, 10 HC Significant reduction in tracer binding in medial temporal
cortex. Significant correlation between [123I]5IA uptake in
left temporoparietal cortex, bilateral temporolimbic areas and
right parahippocampal gyrus and level of cognitive impairment.
[18F]2FA α4β2 nAChR [43] PET 20 AD, 25 HC Significant reduction in α2β4 nAChR availability in thalamus,
caudate, and prefrontal cortex, and medial and lateral temporal
cortices. Significant positive correlation between [18F]2FA
uptake in medial frontal cortex and nucleus basalis of Meynert
and Frontal Assessment Battery test scores in AD patients.
Significant negative correlation between amyloid-β load and
α2β4 nAChR expression in frontal cortex.
AD Alzheimer’s disease, DLB dementia with Lewy bodies, HC healthy control, mAChR muscarinic acetylcholine receptor, MCI mild cognitive
impairment, nAChR nicotinic acetylcholine receptor, PD Parkinson’s disease, PDD Parkinson’s disease dementia, PSP progressive supranuclear palsy
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with cognitive decline [42]. However, other studies have
yielded contrasting results, finding no changes in α4β2
nAChR binding in cortical and thalamic regions of patients
with early AD or MCI compared to healthy controls [36, 41].
This discrepancy may be due to the different severities of
cognitive impairment of the subjects studied and different
methodologies in assessing α4β2 nAChR expression.
PETwith 2-[18F]F-A-85380 ([18F]2FA), a radioligand selec-
tive for α4β2 nAChR, has shown significant reductions in
nAChR availability in the hippocampus, and frontal, temporal
and parietal cortices of AD patients, which furthermore corre-
lated with the level of cognitive impairment [38]. Another
[18F]2FA study showed significantly reduced α4β2 nAChR ex-
pression in the medial frontal cortex and nucleus basalis of
Meynert in AD patients, which were correlated with Frontal
Assessment Battery scores, suggesting that in vivo α4β2
nAChR plays role in those specific functions that may be dif-
ferent from episodic memory [43]. Furthermore, a negative cor-
relation between α4β2 nAChR availability and Aβ load (mea-
sured by [11C]Pittsburgh compound B) was found in the same
brain regions, suggesting that Aβ depositionmay induce degen-
eration of cholinergic neurons [43]. However, [18F]2FA exhibits
slow brain distribution kinetics and relatively low binding po-
tentials (≤0.6 – 0.8) in extrathalamic regions including the cor-
tex which are of high importance in studying neurodegenerative
diseases [68]. In recent years, major effort has focused on the
development of newα4β2 nAChR PET radioligands with faster
regional brain kinetics than [18F]2FA that will enable further
imaging studies in dementia spectrum disorders [69].
Cholinergic imaging in assessing Alzheimer’s disease
treatment
Cholinergic PET imaging techniques have also been
employed to assess the efficacy of medications. PET with
[11C]PMP has shown 19 – 39 % inhibition of cortical AChE
activity following donepezil treatment in AD patients [70, 71]
whereas 28 – 39 % AChE inhibition has been observed after
donepezil and rivastigmine in the frontal temporal and parietal
regions of AD patients using [11C]MP4A PET [72, 73]. Kadir
and colleagues [74] investigated the effect of galantamine, a
cholinesterase inhibitor, on AChE activity and nicotine bind-
ing to nAChR in AD patients. They found significant reduc-
tions in cortical [11C]PMP following galantamine treatment at
3 weeks, and 3 and 12 months compared with baseline [74].
These findings suggest that galantamine treatment is able to
increase ACh concentrations in the synaptic cleft resulting in
increased cholinergic neurotransmission. No significant
changes in [11C]nicotine binding were found following galan-
tamine treatment [74]. Galantamine acts on nAChR as an
allosterically potentiating ligand [75], thereby sensitizing the
receptors, which in turn causes nAChR upregulation to main-
tain a baseline level of signalling.
Cholinergic system in parkinsonian dementias
Parkinson’s disease (PD) is a chronic neurodegenerative dis-
order characterized pathologically by degeneration of dopa-
minergic neurons in the substantia nigra pars compacta and
formation of α-synuclein proteinaceous intraneuronal inclu-
sions referred to as Lewy bodies and Lewy neurites [76–78].
In addition to classical motor symptoms, non-motor features
such as cognitive decline, are a very important aspect of the
disease, because they add significantly to the burden on pa-
tients and caregivers [79, 80]. PD patients carry a sixfold
increased risk for dementia compared to the general popula-
tion, with approximately 80 % of patients developing PD de-
mentia (PDD) over the course of the disease [81, 82]. MCI in
PD also appears to be common, occurring in 20 % to 50 % of
PD patients, even at the time of PD diagnosis and prior to
initiation of dopaminergic therapy [83, 84]. Dementia with
Lewy bodies (DLB) is characterized by fluctuating cognitive
and attentional deficits, recurrent visual hallucinations and
parkinsonism, and is the second most common cause of de-
generative dementia, accounting for 15 – 25 % of cases [85].
Evidence for the involvement of the cholinergic system in the
development of PDD and DLB has been provided by post-
mortem studies, which have shown decreased AChE activity
and nAChR density in cortical and subcortical brain tissue of
PDD and DLB patients [86–92].
Presynaptic cholinergic dysfunction in parkinsonian
dementias
PETstudies using [11C]MP4A and [11C]PMP have demonstrat-
ed mild to moderate decreases in cortical AChE activity in PD
patients without dementia, and severe decreases in PDD and
DLB patients [21, 23, 26]. Using SPECT with [123I]IBVM,
Kuhl et al. [16] demonstrated that whilst in PD without demen-
tia, VAChT levels are reduced only in the parietal and occipital
cortices, in PDD, major losses are seen throughout the entire
cortex, suggesting a greater and more widespread presynaptic
cholinergic dysfunction in PDD patients. Loss of AChE activity
occurs in early stages of the disease, with de novo PD patients
showing significant (12 %) AChE losses in the medial occipital
cortex [24]. Differences in AChE activity between early and
advanced PD are nonsignificant, however, suggesting that cho-
linergic dysfunction occurs early, but does not progress with the
disease [24]. Moreover, loss of cortical AChE activity as mea-
sured by [11C]PMP is correlated with worse performance in
working memory and attention tests but not with the severity
of motor symptoms [23]. A relationship between striatal
[18F]FDOPA uptake and cortical [11C]MPA reduction has been
found in PDD patients, suggesting that cognitive decline in PD
occurs when the disease spreads from nigral neurons to the
cortex, leading to a cholinergic dysfunction in this region [21].
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Cholinergic dysfunction is higher in PDD patients than in
AD patients with a similar degree of cognitive impairment
(MMSE score 22.8 and 22.2, respectively) suggesting that
the mechanisms underlying cognitive decline in PD and AD
have different pathogeneses [19]. In contrast to the cholinergic
system in AD, which was spared (0.7 % reduction), thalamic
AChE activity was found to be decreased by 19.8 % in PDD
patients [28].
Cortical AChE activity differs between patients with PD
and those with progressive supranuclear palsy (PSP) [18,
25]. PD patients show significant decreases in cortical
[11C]MP4A uptake, whereas PSP patients show significant
reductions only in the thalamus [18]. Therefore, a thalamic/
cortical [11C]MP4A binding ratio may be useful in
distinguishing between PD and PSP. A SPECT study using
an [123I]IBVM ligand found that VAChT levels are signifi-
cantly lower in the thalamus and anterior cingulate cortex of
PSP patients compared to healthy controls, and that thalamic
cholinergic dysfunction is inversely correlated with disease
duration [29]. This is in line with the findings of similar PET
studies reported previously, that show a preferential choliner-
gic denervation in the thalamus of PSP patients [83]. VAChT
levels, however, are unaffected in the striatum of PSP patients
[29]. This differs from PD pathology, in which cholinergic
neurons in the striatum are affected, suggesting a possible role
of cholinergic imaging markers in aiding the differential diag-
nosis of these two clinically similar diseases [29].
In other atypical parkinsonisms such as multiple system
atrophy, cortical AChE activity decreases have been found to
be similar to those seen in PD patients (−14.6 % and −15.3 %,
respectively) [25]. Hirano et al. [27] investigated differences
in AChE activity in patients with PSP, corticobasal degenera-
tion (CBD) and frontotemporal dementia (FTD) using both
voxel-based and volume of interest analysis. Statistical para-
metric mapping analysis showed significant AChE decreases
in the paracentral region, frontal, parietal and occipital cortices
in CBD patients and in the paracentral region and thalamus in
PSP patients [27]. FTD patients showed no significant differ-
ences in AChE activity compared to the control group.
Volume of interest analysis showed significant decreases in
thalamic AChE activity only in PSP patients. Thus, choliner-
gic dysfunction occurs in CBD and PSP, although involving
different brain regions, but it was not observed in FTD pa-
tients, whichmay explain whyAChE inhibitors are ineffective
for this condition [93].
Postsynaptic cholinergic dysfunction in parkinsonian
dementias
Post-mortem studies have shown that cortical mAChR density
is altered in PDD and DLB samples [94, 95]. An in vivo PET
study with N - [ 11C]methyl -4-p iper idyl benzi la te
([11C]NMPB), a marker for mAChR, demonstrated increased
mAChR levels in the frontal cortex of PD patients, probably
due to denervation hypersensitivity caused by loss of the as-
cending cholinergic system in frontal areas [30].
Contrastingly, in PSP patients, cortical and thalamic
[11C]NMPB binding was preserved [30]. A SPECT study
using [123I]iodo-quinuclidinyl benzilate ([123I]QNB), another
marker for mAChR, showed significant increases in mAChR
in the occipital lobe in both PDD and DLB, which may be the
substrate of visual disturbances in these diseases [31].
Furthermore, there was significantly lower [123I]QNB binding
in the frontal and temporal lobes of PDD patients than in DLB
patients. [11C]NMPB and [123I]QNB are high-affinity
mAChR antagonists with similar chemical structures and re-
gional brain distributions [96–98]. Both radioligands pene-
trate the blood–brain barrier efficiently but nonspecifically in
relation to mAChR subtype [99].
[123I]5IA SPECTstudies have shown 10 – 25 % reductions
in nAChR levels in cortical and subcortical regions of PD
patients [33, 95], with the largest decreases observed in the
thalamus, and parietal and temporal cortices [33]. A [18F]2FA
PET study showed significant reductions in α4β2 nAChR
availability in various regions in PD patients, including the
frontoparietal and anterior cingulate cortices, midbrain, pons
and cerebellum, with the highest reduction in the left parietal
cortex [40]. Furthermore, α4β2 nAChR loss correlated with
depression and cognitive decline as measured by the MMSE,
the DemTect Scale, the Clock Drawing test, delayed recall of
figures of the CERAD (Consortium to Establish a Registry for
Alzheimer’s Disease) battery, and the Trail Making test [40].
In nondemented PD patients, cortical and subcortical
[123I]5IA decreases correlated with worse performance In
the Boston Naming test and Word List Intrusions test, two
specific tests for detection of word-finding difficulties, learn-
ing capacity and memory for language information [98].
Decreases in [18F]2FA uptake were also found in the striatum
(−10%) and substantia nigra (−14.9%) of PD patients, but did
not correlate with dopaminergic function as measured by
[18F]F-DOPA, nor with clinical severity [39].
[123I]5IA SPECT has shown significant reductions inα4β2
nAChR binding in the frontal, temporal and cingulate cortex,
as well as in the striatum of DLB patients [37]. In the occipital
cortex, however, α4β2 nAChR levels were increased and cor-
related with visual hallucinations experienced by DLB pa-
tients, suggesting cholinergic dysfunction in the occipital lobe
as a substrate of visual hallucinations. Because α4β2 nAChRs
are located in some regions presynaptically on both choliner-
gic and noncholinergic terminals [101], some difficulties may
arise in the interpretation of nAChR imaging studies. In PD,
significantly decreased α4β2 nAChR levels may be a result of
nAChR loss on degenerated presynaptic nigrostriatal dopami-
nergic neurons. A post-mortem study has shown that loss of
striatal nAChR binding closely parallels the loss of
nigrostriatal dopaminergic markers in PD brain tissue [102].
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Postsynaptic nAChR receptors may show a compensatory in-
crease, no change, or a decrease due to degeneration of
noncholinergic systems (e.g. noradrenergic, serotoninergic,
glutamatergic) to which the nAChRs are coupled [37, 102].
Further studies combining cholinergic and noncholinergic
radioligands may aid in elucidating the nAChR alteration pat-
terns in parkinsonian disorders.
Conclusion
Cholinergic dysfunction has a pivotal role in the pathophysiol-
ogy of cognitive decline. Given the wide variety of available
markers for the cholinergic system, molecular imaging tech-
niques provide a valuable tool to investigate pathophysiological
mechanisms, and monitor progression and response to treat-
ments in AD and parkinsonian dementia. The largest drawback
of this technology, its cost, will hopefully be improved by its
widening use as it becomes increasingly clear that PET and
SPECT imaging holds much potential for gleaning important
information about the pathology of dementia. Much remains to
be learned about cholinergic dysfunction in AD, PD and related
disorders. PET studies combining presynaptic and postsynaptic
radioligands may be useful in unravelling alterations of cholin-
ergic neurotransmission. Moreover, it has been suggested that
the α7 nAChR subtype may have a neuroprotective role by
modulating the neurotrophic system crucial for themaintenance
of cholinergic neuron integrity, and also by stimulating signal
transduction pathways that support neuron survival [103]. In
AD, α7 nAChR may modulate β-amyloid-induced pathology
[104], and deletion of the α7 nAChR gene has shown to im-
prove cognitive impairment in animal models of AD [105].
Further PET studies using radioligands specific to the α7
nAChR such as [18F]ASEM [106, 107] are needed to determine
the relationship between α7 nAChR and AD pathology.
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